3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
2
Carcinoma, Transitional Cell
2
Urologic Neoplasms
1
Squamous Cell Lung Cancer
1
Pancreatic Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Neuronopathy, Distal Hereditary Motor, Type IIB
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
156
Gemcitabine
139
Capecitabine
121
Paclitaxel
119
Fluorouracil
116
Oxaliplatin
110
Bevacizumab
104
Nivolumab
97
Leucovorin
97
Docetaxel
93
Cisplatin
90
Irinotecan
88
Carboplatin
85
Radiosurgery
83
Cyclophosphamide
71
Cetuximab
70
Magnetic Resonance Spectroscopy
68
Trastuzumab
56
Specimen Handling
56
Biopsy
56
Radiotherapy
55
Ipilimumab
52
Everolimus
48
Pemetrexed
46
Drug Therapy
45
Albumin-Bound Paclitaxel
44
130-nm albumin-bound paclitaxel
43
Doxorubicin
41
Fulvestrant
38
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm Metastasis
×
apatorsen
×
Clear all
NCT01844817
2017-05-16
Rainier
SCRI Development Innovations, LLC
Phase 2
Completed
132 enrolled
9 charts